nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo journalinfonormal searchdiv searchzone qikanlogo popupnotification paper paperNew
2025, 05, v.16 392-397
2019—2023年江苏省南京市高淳区9~26岁女性人乳头瘤病毒疫苗接种情况分析
基金项目(Foundation):
邮箱(Email): 517625683@qq.com;
DOI: 10.19757/j.cnki.issn1674-7763.2025.05.007
摘要:

目的 分析江苏省南京市高淳区9~26岁女性人乳头瘤病毒(human papillomavirus,HPV)疫苗接种情况,旨在了解本地区年轻女性HPV疫苗接种率,为完善HPV疫苗免疫策略提供科学依据。方法 收集江苏省预防接种综合服务管理信息系统中2019—2023年南京市高淳区9~26岁女性二价、四价和九价HPV疫苗接种信息,采用累计接种率和构成比指标对接种数据进行描述性分析,采用χ2检验方法对不同年份、地区、年龄、职业女性的3种HPV疫苗接种累计剂次构成进行比较。结果2019—2023年南京市高淳区9~26岁女性HPV疫苗累计首剂、全程接种率分别为28.39%、23.40%。其中9~14岁女性累计首剂接种率最低(16.10%),15~19岁女性累计全程接种率最低(11.77%),20~26岁女性累计首剂接种率(50.82%)和全程接种率均最高(43.55%)。农村地区二价HPV疫苗接种占比(16.09%)高于城市和城郊地区,9~14岁年龄女性二价HPV疫苗接种比例最高(52.60%),高等教育院校学生九价HPV接种比例最高(99.34%)。不同年份(χ2=1 617.71)、地区(χ2=251.90)、年龄(χ2=12 750.12)、职业(χ2=4 584.26)女性的3种HPV疫苗累计接种剂次构成比差异均有统计学意义(均P<0.001)。结论 南京市高淳区9~26岁女性HPV疫苗接种率偏低,农村地区HPV疫苗累计接种剂次数最低,年轻女性倾向于选择九价HPV疫苗。建议扩展在校学生接种优惠政策的年龄范围,引入医保账户支付方式,以及增加重点人群预防接种服务供给,应重点关注9~14岁女性HPV疫苗接种率。

Abstract:

Objective An analysis of the human papillomavirus(HPV) vaccination status among females aged 9-26 years in Gaochun district of Nanjing city, Jiangsu province, was conducted to ascertain the vaccination coverage among young females in the region and to provide a scientific foundation for optimizing immunization strategies. Methods Data on the administration of bivalent,quadrivalent, and nonavalent HPV vaccines among females aged 9-26 years in Gaochun district of Nanjing city, from 2019-2023,were collected from the Jiangsu Province Comprehensive Vaccination Service Management Information System. Descriptive analysis of HPV vaccination data was conducted using cumulative vaccination rates and composition ratio metrics. Additionally, the χ2 test was employed to compare the cumulative doses of the three HPV vaccines across different years, regions, age groups, and occupations.Results From 2019-2023, the cumulative first-dose and full-course HPV vaccination rates among females aged 9-26 years in Gaochun District were 28.39% and 23.40%, respectively. Among them, females aged 9-14 years had the lowest cumulative first-dose vaccination rate(16.10%), while those aged 15-19 years had the lowest full-course vaccination rate(11.77%). In contrast,females aged 20-26 years showed the highest cumulative first-dose(50.82%) and full-course vaccination rates(43.55%). The proportion of bivalent HPV vaccine administration was higher in rural areas(16.09%) than in urban and suburban regions, with females aged 9-14 years showing the highest bivalent vaccine uptake(52.60%). Students from higher education institutions had the highest nonavalent HPV vaccine uptake(99.34%). Statistically significant differences were observed in the cumulative dose composition of the three HPV vaccine types across different years(χ2 = 1 617.71), regions(χ2 = 251.90), age groups(χ2 = 12 750.12), and occupations(χ2 =4 584.26)(all P < 0.001). Conclusion The HPV vaccination rate among females aged 9-26 years in Gaochun district of Nanjing city remains low, with the lowest cumulative doses administered in rural areas. Young females tend to prefer the nonavalent HPV vaccine. It is suggested that age range for subsidized vaccination policies be extended, payment through medical insurance accounts be introduced,and preventive vaccination services for key demographics be enhanced, particularly focusing on improving vaccination rates among females aged 9-14 years.

参考文献

[1]Jain M, Yadavd, Jarouliya U, et al. Epidemiology,molecular pathogenesis,immuno-pathogenesis,immune escape mechanisms and vaccine evaluation for HPVassociated carcinogenesis[J]. Pathogens,2023,12(12):1380.

[2]Shah R, Nwankwo C, Kwon Y, et al. Economic and humanistic burden of cervical cancer in the united states:results from a nationally representative survey[J]. J Womens Health(Larchmt),2020,29(6):799-805.

[3]Petca A,Borislavschi A,Zvanca ME,et al. Non-sexual HPV transmission and role of vaccination for a better future(review)[J]. Exp Ther Med,2020,20(6):186.

[4]Filho AM,Laversanne M,Ferlay J,et al. The globocan2022 cancer estimates:data sources, methods, and a snapshot of the cancer burden worldwide[J]. International journal of cancer,2025,156(7):1336-1346.

[5]郑荣寿,陈茹,韩冰峰,等. 2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.

[6]Luo L, He P, Liu Q, et al. Prevalence and genotype distribution of HPV infection among 214 715 women from southern China, 2012-2018:baseline measures prior to mass HPV vaccination[J]. BMC Infectious Diseases,2021,21(1):328.

[7]Liu Y,Zhang Q,Hu S,et al. Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China[J]. BMC Cancer,2016,16(1):164.

[8]World Health Organization. HPV dashboard[EB/OL].(2025-04-07)[2025-05-06]. https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/humanpapillomavirus-vaccines-(HPV)/hpv-clearing-house/hpv-dashboard.

[9]Cody P,Tobe K,Abe M,et al. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan:a model-based study[J]. BMC Infect Dis,2021,21(1):11.

[10]康国栋,汪志国,胡冉,等.基于云平台的江苏省预防接种综合服务管理信息系统建设与应用[J].中国疫苗和免疫,2020,26(4):450-454.

[11]崔芳芳,鲍俊哲,王琳琳,等. 1990—2019年中国女性“两癌”疾病负担变化趋势及预测分析[J].中国卫生统计,2022,39(5):647-652.

[12]Chen J, Zhang Z, Pan W, et al. Estimated human papillomavirus vaccine coverage among females 9-45years of age-China, 2017-2022[J]. China CDC weekly,2024,6(19):413-417.

[13]陈伟,李彦坤,吴小丽,等. 2018—2021年天津市适龄女性人乳头瘤病毒疫苗接种率分析[J].中国疫苗和免疫,2022,28(6):684-689.

[14]王保山,杨阳. 2017—2022年山东省德州市德城区9~45岁女性HPV疫苗接种情况分析[J].中国妇幼卫生杂志,2024,15(4):1-4.

[15]胡璐,蒋加诚,高颖漫,等.差异化HPV疫苗接种——基于我国女大学生异质性特点分析[J].现代预防医学,2024,51(19):3626-3630.

[16]World Health Organization. Human papillomavirus(HPV)vaccination coverage[EB/OL].(2024-07-15)[2025-05-06]. https://immunizationdata.who.int/global/wiise-detail-page/human-papillomavirus-(hpv)-vaccination-coverage.

[17]Lei J, Ploner A, Elfstrom KM, et al. HPV vaccination and the risk of invasive cervical cancer[J]. The New England journal of medicine,2020,383(14):1340-1348.

[18]Kjaer SK,Dehlendorff C,Belmonte F,et al. Real-world effectiveness of human papillomavirus vaccination against cervical cancer[J]. Journal of the National Cancer Institute,2021,113(10):1329-1335.

[19]Xie Y,Su L,Wang F,et al. Awareness regarding and vaccines acceptability of human papillomavirus among parents of middle school students in Zunyi, Southwest China[J]. Human vaccines&immunotherapeutics,2021,17(11):4406-4411.

[20]郑文新,叶瑜,许伟杰,等.农村女性人乳头瘤病毒疫苗接种情况研究综述[J].中国农村卫生,2022,14(11):70-72.

[21]刘书君,乔友林,周彩虹.多源流理论视角下HPV疫苗纳入免疫规划政策分析[J].中国公共卫生,2023,39(3):273-278.

[22]中国疫苗行业协会免疫规划规范化管理与实践分会.青少年女性人乳头瘤病毒疫苗免疫策略与实践长三角地区专家共识[J].中华预防医学杂志,2023,57(2):135-153.

[23]Wang L, Zhong Y, Di J. Current experience in HPV vaccination in China[J]. Indian Journal of Gynecologic Oncology,2021,19(3):50.

基本信息:

DOI:10.19757/j.cnki.issn1674-7763.2025.05.007

中图分类号:R737.33;R186

引用信息:

[1]张杨,周冬颖.2019—2023年江苏省南京市高淳区9~26岁女性人乳头瘤病毒疫苗接种情况分析[J].中国妇幼卫生杂志,2025,16(05):392-397.DOI:10.19757/j.cnki.issn1674-7763.2025.05.007.

检 索 高级检索